The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide |
| |
Authors: | Zacarías Fluck Mariano F Hess Leonardo Salatino Mariana Croci Diego O Stupirski Juan C Di Masso Ricardo J Roggero Eduardo Rabinovich Gabriel A Scharovsky O Graciela |
| |
Affiliation: | (1) Instituto de Gen?tica Experimental, Facultad de Ciencias M?dicas, Universidad Nacional de Rosario (UNR), Santa Fe 3100, S2002KTR Rosario, Argentina;(2) Laboratorio de Inmunopatolog?a, Instituto de Biolog?a y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Cient?ficas y T?cnicas (CONICET), Vuelta de Obligado 2490, C1428 Ciudad de Buenos Aires, Argentina;(3) Departamento de Qu?mica Biol?gica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina;(4) Present address: Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; |
| |
Abstract: | Although lymphomas account for almost half of blood-derived cancers that are diagnosed each year, the causes of new cases are poorly understood, as reflected by the relatively few risk factors established. Galectin-1, an immunoregulatory ?-galactoside-binding protein, has been widely associated with tumor-immune escape. The aim of the present work was to study the relationship between tumor growth rate, aggressiveness, and response to cyclophosphamide (Cy) therapy with regard to Gal-1 expression in murine T-cell lymphoma models. By means of a disruptive selection process for tumor growth rate, we generated two lymphoma variants from a parental T-cell lymphoma, which have unique characteristics in terms of tumor growth rate, spontaneous regression, metastatic capacity, Gal-1 expression and sensitivity to Cy therapy. Here, we show that Gal-1 expression strongly correlates with tumor growth rate, metastatic capacity and response to single-dose Cy therapy in T-cell lymphoma models; this association might have important consequences for evaluating prognosis and treatments of this type of tumors. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|